J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?

Johnson & Johnson JNJ announced strong second-quarter results earlier this month. The drug and medical device giant beat estimates for both earnings and sales. Despite the loss of exclusivity (“LOE”) of its blockbuster drug, Stelara, its Innovative Medicine unit once again outperformed expectations, with sales of all key drugs Darzalex,...